Ridge Preservation Using a Ossix™ Bone vs Bio-Oss® Collagen

Sponsor
Datum Dental LTD (Industry)
Overall Status
Completed
CT.gov ID
NCT04338516
Collaborator
(none)
45
1
2
28.3
1.6

Study Details

Study Description

Brief Summary

This randomized, parallel design, controlled study will assess the histologic healing of this Ossix™ Bone in humans and compare it to a Bio-Oss® Collagen that is well researched.

Subjects will be enrolled into 2 groups. Each subject will provide a single non-molar tooth site for study treatment. The tooth will be extracted, the extraction socket will be filled with one of the study bone grafts. No wound dressing or membrane will be used to cover the bone graft material as both materials can be used alone. An core biopsy will be collected after 16 weeks of healing during the implant placement.

The study will evaluate if there is a difference in histologic wound healing following tooth extraction and ridge preservation between groups treated with Bio-Oss® Collagen compared to Ossix™ Bone.

Condition or Disease Intervention/Treatment Phase
  • Device: Ossix™ Bone
  • Device: Bio-Oss® Collagen
Phase 4

Study Design

Study Type:
Interventional
Actual Enrollment :
45 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Histological Evaluation of Healing Following Ridge Preservation Using a Composite Bovine Derived Xenograft or a Hydroxyapatite-Collagen Matrix
Actual Study Start Date :
Nov 1, 2019
Actual Primary Completion Date :
Dec 30, 2021
Actual Study Completion Date :
Mar 10, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Bio-Oss® Collagen,

subjects treated with Bio-Oss® Collagen, (Geistlich, Inc.)

Device: Bio-Oss® Collagen
90% bovine derived xenograft granules and 10% porcine collagen

Experimental: Ossix™ Bone

subjects treated with Ossix™ Bone (Datum Dental Ltd)

Device: Ossix™ Bone
a resorbable sponge-like matrix of 80% hydroxyapatite and 20% sugar cross-linked porcine collagen

Outcome Measures

Primary Outcome Measures

  1. percent vital bone formation, [16 weeks]

    shows the amount of new bone formed after the procedure

  2. percent residual graft material [16 weeks]

    shows how much of the graft material remained intact

  3. percent fibrous tissue and marrow space [16 weeks]

    amount of tissue that is neither native bone or graft material

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • One tooth, excluding molars, that has been identified by dental faculty as requiring a single tooth extraction

  • A dental implant is indicated and treatment planned to replace the missing tooth

  • Have adequate restorative space for a dental implant-retained restoration

  • Have at least 10mm of alveolar bone height, without impinging on the maxillary sinus or inferior alveolar canal.

  • Have a dehiscence of the buccal or lingual bony plate of the tooth socket extending no more than 50% of the total depth of the socket.

  • Female patients who have undergone a hysterectomy, tubal ligation, or menopause, and non-pregnant women of child-bearing potential.

  • Are nonsmokers or former smokers. Current smokers may be included if they smoke <10 cigarettes per day

Exclusion Criteria:
  • Will not cooperate with the follow-up schedule. Patients will not be entered who are mentally incompetent, prisoners, or pregnant.

  • Pregnant women or women intending to become pregnant during the study period (as confirmed verbally; an over the counter pregnancy test will be provided if pregnancy status is unknown or suspected).

  • Patients who become pregnant during the study will be withdrawn and standard care will be delivered.

  • Smokers who smoke >10 cigarettes per day

  • Clinical and/or radiographic determinations which will preclude inclusion in this study are: Active infection other than periodontitis; Inadequate bone dimensions or restorative space for a dental implant; Presence of a disease entity, condition or therapeutic regimen which decreases probability of soft tissue and bony healing, e.g., poorly controlled diabetes, chemotherapeutic and immunosuppressive agents, autoimmune diseases, history of bisphosphonate use or long-term steroid therapy; Positive medical history of endocarditis following oral or dental surgery.

Contacts and Locations

Locations

Site City State Country Postal Code
1 UT Health San Antonio (UTHSA) San Antonio Texas United States 78229-3900

Sponsors and Collaborators

  • Datum Dental LTD

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Datum Dental LTD
ClinicalTrials.gov Identifier:
NCT04338516
Other Study ID Numbers:
  • HSC20190455H
First Posted:
Apr 8, 2020
Last Update Posted:
Apr 5, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes

Study Results

No Results Posted as of Apr 5, 2022